Answers are grounded in this paper and cite their sources.
Demonstrates enhanced tumor visualization with novel nanoparticles, suggesting improved cancer diagnosis.
The development of high‐performance contrast agents in magnetic resonance imaging (MRI) has recently received considerable attention, as they hold great promise and potential as a powerful tool for cancer diagnosis. Despite substantial achievements, it remains challenging to develop nanostructure‐based biocompatible platforms that can generate on‐demand MRI signals with high signal‐to‐noise ratios and good tumor specificity. Here, the design and synthesis of a new class of nanoparticle‐based contrast agents comprising self‐assembled NaGdF 4 and CaCO 3 nanoconjugates is reported. In this design, the spatial confinement of the T 1 source (Gd 3+ ions) leads to an “OFF” MRI signal due to insufficient interaction between the protons and the crystal lattices. However, when immersed in the mildly acidic tumor microenvironment, the embedded CaCO 3 nanoparticles generate CO 2 bubbles and subsequently disconnect the nanoconjugate, thus resulting in an “ON” MRI signal. The in vivo performance of these nanoconjugates shows more than 60‐fold contrast enhancement in tumor visualization relative to the commercially used contrast agent Magnevist. This work presents a significant advance in the construction of smart MRI nanoprobes ideally suited for deep‐tissue imaging and target‐specific cancer diagnosis.
No takes yet. Share an insight, caveat, or question.
Yi et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: